Pulmonx Corp
$ 1.27
-6.27%
21 Jul - close price
- Market Cap 53,641,000 USD
- Current Price $ 1.27
- High / Low $ 1.34 / 1.21
- Stock P/E N/A
- Book Value 1.08
- EPS -1.30
- Next Earning Report 2026-07-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.86 %
- 52 Week High 3.86
- 52 Week Low 1.13
About
Pulmonx Corporation, a medical technology company, designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. The company is headquartered in Redwood City, California.
Analyst Target Price
$3.40
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-29 | 2026-03-04 | 2025-11-12 | 2025-07-30 | 2025-04-30 | 2025-02-19 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-10-30 | 2023-08-02 |
| Reported EPS | -0.33 | -0.25 | -0.34 | -0.38 | -0.36 | -0.33 | -0.36 | -0.35 | -0.36 | -0.36 | -0.39 | -0.43 |
| Estimated EPS | -0.33 | -0.3948 | -0.42 | -0.4 | -0.4 | -0.45 | -0.45 | -0.43 | -0.46 | -0.41 | -0.43 | -0.44 |
| Surprise | 0 | 0.1448 | 0.08 | 0.02 | 0.04 | 0.12 | 0.09 | 0.08 | 0.1 | 0.05 | 0.04 | 0.01 |
| Surprise Percentage | 0% | 36.6768% | 19.0476% | 5% | 10% | 26.6667% | 20% | 18.6047% | 21.7391% | 12.1951% | 9.3023% | 2.2727% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-29 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LUNG
2026-07-15 20:10:55
Pulmonx Corporation announced it will release its second-quarter 2026 financial results on Wednesday, July 29, 2026, after the close of trading. The company will host a conference call to discuss these results at 1:30 p.m. PT / 4:30 p.m. ET, with a webcast available on its investor relations website. Pulmonx is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD).
2026-07-15 19:41:18
Pulmonx (Nasdaq: LUNG) announced it will release its second-quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, which will be accessible via their investor relations website. This announcement notes a mixed historical market reaction to similar notices, with an average stock move of 1.66%.
2026-07-09 20:45:19
Pulmonx (NASDAQ:LUNG) is attracting attention as a penny stock due to its focus on severe emphysema treatment. The company's key products, the Zephyr Endobronchial Valve and the Chartis system, are highlighted for their role in improving lung function in affected patients. This renewed interest is driven by the strength of the healthcare sector and Pulmonx's innovative medical devices.
2026-07-07 19:32:00
Pulmonx Corp positions itself as a specialized medical technology company focusing on minimally invasive devices for severe emphysema and chronic respiratory conditions. Its business model centers on bronchoscopic procedures, generating revenue from implantable devices and associated delivery systems used by specialist physicians. The company's strategy emphasizes regulatory clearances, reimbursement, and clinical evidence to drive adoption and long-term growth in the respiratory care market.
2026-07-05 06:09:24
This page from TradingView provides financial information for Pulmonx Corp. under the ticker LSX:A2P1AF. It focuses on the enterprise value to EBITDA forward metric, but the actual data values are not visible in the provided content. The page also includes various navigation and informational links related to trading and financial analysis tools.
2026-07-05 04:39:39
This article focuses on the "Enterprise value to EBIT forward" metric for Pulmonx Corp. (LSX:A2P1AF). It appears to be a financial data snippet from TradingView, providing an overview of a specific valuation ratio for the company's stock. The content points to financial data available on the platform, indicating market and company-specific information.
